Two SRIF agonists are available for treatment of acromegaly; octreotide (Novartis) and lanreotide (Ipsen). Both short and long-acting derivatives of these molecules have been developed. Octreotide compounds are approved for clinical use in the USA, while both lanreotide and octreotide compounds are approved for use elsewhere.